The FDA has finalized the design of its Expedited Investigational New Drug (IND) Pilot and began accepting applications from sponsors paired with qualified research institutions to accelerate first-in-human timelines. The agency framed the move as part of broader efforts to remove regulatory friction and keep early clinical development competitive globally. According to the FDA’s announcement, the pilot is intended to speed the IND process from identifying a drug to initiating a first-in-human study by pairing drug companies with qualified research institutions (QRI) equipped to support efficient IND submissions. Applications are being accepted until October 30, 2026, with the FDA’s structure centered on rolling submissions and qualification of participating entities. Separate reporting also indicates the agency has incorporated public feedback into who can qualify under the pilot. A related update emphasizes the FDA is actively refining how it approaches IND-related review timing and qualification criteria—an effort that could materially affect how sponsors plan early development strategies and data packages.